TY - JOUR
T1 - Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients
T2 - Nationwide quality assurance in the netherlands
AU - van Breeschoten, Jesper
AU - van den Eertwegh, Alfonsus J. M.
AU - de Wreede, Liesbeth C.
AU - Hilarius, Doranne L.
AU - van Zwet, Erik W.
AU - Haanen, John B.
AU - Blank, Christian U.
AU - Aarts, Maureen J. B.
AU - van den Berkmortel, Franchette W. P. J.
AU - de Groot, Jan Willem B.
AU - Hospers, Geke A. P.
AU - Kapiteijn, Ellen
AU - Piersma, Djura
AU - van Rijn, Rozemarijn S.
AU - Stevense‐den Boer, Marion A. M.
AU - van der Veldt, Astrid A. M.
AU - Vreugdenhil, Gerard
AU - Boers‐sonderen, Marye J.
AU - Suijkerbuijk, Karijn P. M.
AU - Wouters, Michel W. J. M.
N1 - Funding Information: For the Dutch Melanoma Treatment Registry (DMTR), the Dutch Institute for Clinical Auditing foundation received a start?up grant from governmental organization The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol Myers Squibb, Merck Sharpe & Dohme, Novartis and Roche Pharma. Roche Pharma stopped funding in 2019 and Pierre Fabre started funding of the DMTR in 2019. For this work, no funding was granted. Funding Information: Funding: For the Dutch Melanoma Treatment Registry (DMTR), the Dutch Institute for Clinical Au‐ diting foundation received a start‐up grant from governmental organization The Netherlands Or‐ ganization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol Myers Squibb, Merck Sharpe & Dohme, Novartis and Roche Pharma. Roche Pharma stopped funding in 2019 and Pierre Fabre started funding of the DMTR in 2019. For this work, no funding was granted. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10/2
Y1 - 2021/10/2
N2 - Background: To assure a high quality of care for patients treated in Dutch melanoma centers, hospital variation in treatment patterns and outcomes is evaluated in the Dutch Melanoma Treatment Registry. The aim of this study was to assess center variation in treatments and 2‐year survival probabilities of patients diagnosed between 2013 and 2017 in the Netherlands. Methods: We selected patients diagnosed between 2013 and 2017 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. Centers’ performance on 2‐year survival was evaluated using Empirical Bayes estimates calculated in a random effects model. Treatment patterns of the centers with the lowest and highest estimates for 2‐year survival were compared. Results: For patients diagnosed between 2014 and 2015, significant center variation in 2‐ year survival probabilities was observed even after correcting for case‐mix and treatment with new systemic therapies. The different use of new systemic therapies partially explained the observed variation. From 2016 onwards, no significant difference in 2‐year survival was observed between centers. Conclusion: Our data suggest that between 2014 and 2015, after correcting for patient case-mix, significant variation in 2‐year survival probabilities between Dutch melanoma centers existed. The use of new systemic therapies could partially explain this variation. In 2013 and between 2016 and 2017, no significant variation between centers existed.
AB - Background: To assure a high quality of care for patients treated in Dutch melanoma centers, hospital variation in treatment patterns and outcomes is evaluated in the Dutch Melanoma Treatment Registry. The aim of this study was to assess center variation in treatments and 2‐year survival probabilities of patients diagnosed between 2013 and 2017 in the Netherlands. Methods: We selected patients diagnosed between 2013 and 2017 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. Centers’ performance on 2‐year survival was evaluated using Empirical Bayes estimates calculated in a random effects model. Treatment patterns of the centers with the lowest and highest estimates for 2‐year survival were compared. Results: For patients diagnosed between 2014 and 2015, significant center variation in 2‐ year survival probabilities was observed even after correcting for case‐mix and treatment with new systemic therapies. The different use of new systemic therapies partially explained the observed variation. From 2016 onwards, no significant difference in 2‐year survival was observed between centers. Conclusion: Our data suggest that between 2014 and 2015, after correcting for patient case-mix, significant variation in 2‐year survival probabilities between Dutch melanoma centers existed. The use of new systemic therapies could partially explain this variation. In 2013 and between 2016 and 2017, no significant variation between centers existed.
KW - Advanced melanoma
KW - Center variation
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85116757063&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/cancers13205077
DO - https://doi.org/10.3390/cancers13205077
M3 - Article
C2 - 34680228
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 20
M1 - 5077
ER -